RTK Group is a family office backed biopharmaceutical advisory and investment fund focused on emerging technologies having disruptive impact and significant potential to benefit patients.
We focus our efforts where we can leverage our unique expertise in company formation and technology development to assist high‐performing management teams realize the full value potential of their technology.
Committed to Making Game-Changing Healthcare Contributions
Team of experienced life‐science professionals with experience across all sectors of health care
Long-Term Investor With Innovative Solutions
Improving the World – One Investment at a Time
We embrace scientific risk and support research with high impact potential. Our belief is that investing in promising concepts backed by solid science creates the potential for significant value creation.
High performing teams are critical to allow promising technologies to realize their full potential. We back innovators at all stages of their entrepreneurial career and support teams as needed with our expertise in company formation and technology development.
Our ultimate goal is to improve the human condition through our support of technology development. Leaving the potential for a better future for our future generations is what motivates us to foster scientific innovation and teams dedicated to improving patient lives.
Founding Partner
Dr. Kohli founded RTK Group in December 2019. Dr. Kohli has served as an Attending Physician and Associate Professor with the Tufts University School of Medicine for 20 years in the Department of Medicine, Division of Geographic Medicine and Infectious Diseases, with clinical focus areas of transplant medicine, HIV infection and insulin resistance.
In addition to her career in academic medicine, Dr. Kohli has been extensively involved in academic and commercial research, being awarded a NIH K23 award early in her scientific career and receiving a developmental award from the Center for AIDS Research, generating numerous publications and invited presentations. Dr. Kohli has assisted numerous companies across all aspects of development and strategy, including serving as the lead investigator on several pivotal clinical studies, consultant on clinical development strategy, and market analysis.
Dr. Kohli completed her residency in Internal Medicine at the Beth Israel Deaconess Medical Center and fellowship in Infectious Disease at the Albert Einstein College of Medicine. Dr. Kohli received her MD from the University of Rochester School of Medicine and Dentistry, and a BS in Biological Sciences from Cornell University. Dr. Kohli recognized as a Castle Connolly Top Doctor for the last four years for her clinical practice excellence as well as recognized by Boston Magazine in their Top Doctors 2025 list.
Managing Director, RTK Group
Dr. Muni has been a Managing Director of RTK Group since January 2020. Dr. Muni is an accomplished life sciences executive with 25 years of industry experience as an operator, investor, and advisor to multiple biotechnology and pharmaceutical companies, leveraging unique insights gained through a career spanning industry, healthcare investment banking, the FDA, and clinical care.
Prior to RTK Group, Dr. Muni served as the CEO of Azurity Pharmaceuticals, a commercial-stage pharmaceutical company focused on developing therapeutics for patients with high unmet need, including children and the elderly. During his tenure as CEO, Dr. Muni achieved a successful investor exit through sale of the company to private equity upon receiving FDA approval of the company’s lead program. Prior to Azurity, Dr. Muni served as the Head of New Product Planning and Corporate Strategy at Sunovion Pharmaceuticals. Prior to that, Dr. Muni was an engagement manager at the healthcare investment bank Leerink Swann. Prior to Leerink, he was a Medical Officer in the Division of Cardiovascular Devices at the FDA.
Over the past 25 years, Dr. Muni has maintained staff appointments at Harvard Medical School and its leading teaching hospitals, including Brigham and Women’s Hospital and the Dana Farber Cancer Institute, where he continues to actively practice medicine and teach medical residents and students several weeks per year as an Associate Physician within the MassGeneral Brigham Hospital Medicine Unit. Dr. Muni is also appointed as a Visiting Scholar at Harvard University’s Wyss Institute for Biologically Inspired Engineering, mentoring project teams on technology development, entrepreneurship and company formation. Dr. Muni also devotes his time mentoring founders of startup teams through the MassBio Drive accelerator program and is a mentor with the University of Toronto Rotman School of Business’ Creative Destruction Lab startup accelerator program. Dr. Muni completed his residency in Internal Medicine at the Brigham and received his MD as well as Master of Science in Public Health (biostatistics) from the Tulane University School of Medicine, and a BA in Business Economics and B.Sc. in Biochemistry from Brown University.
Senior Associate, Finance
Senior Associate, Operations
Ph.D. Associate
RTK is a biopharmaceutical advisory and investment fund that supports companies
by enabling them to develop promising technologies and reach their potential to benefit patients.
We have one goal: to enable better patient lives and a better world through better healthcare. We take great satisfaction in partnering with companies having high potential to disrupt the healthcare ecosystem and helping support high‐performing management teams to realize their goals.